Last reviewed · How we verify
NCT06850285
CD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma
NA trial testing chimeric antigen receptor gene modified T cells in Lymphoma, B-Cell in 15 participants. Currently enrolling.
1 June 2028
Quick facts
| Lead sponsor | Shanxi Bethune Hospital |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 15 |
| Start date | 5 September 2025 |
| Primary completion | 1 June 2028 |
| Estimated completion | 1 June 2028 |
| Sites | 1 location across China |
Drugs / interventions tested
- chimeric antigen receptor gene modified T cells — full drug profile →
Conditions studied
- Lymphoma, B-Cell — all drugs for Lymphoma, B-Cell →
Sponsor
Shanxi Bethune Hospital
Who can join
Adults 15 to 80, any sex, with Lymphoma, B-Cell. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The is a prospective, open-label, dose-climbing clinical study assessing the efficacy and safety of CD30 CAR-T in the treatment of r/r CD30+ lymphoma. Plan to recruit 15 subjects with r/r CD30+ lymphoma。
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Mechanisms of Resistance to CAR T-Cells and How to Overcome Them.
Legato L, Bisio M, Fasano F, Benevolo Savelli C, et al · · 2025 · cited 3× · PMID 40981226 · DOI 10.3390/mps8050108
Verify or expand the search:
- PubMed search for NCT06850285
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of chimeric antigen receptor gene modified T cells
Trials testing the same drug.
- NCT07048353 — CD30 CAR-T in the Treatment of CD30 Positive Lymphoma · EARLY_PHASE1 · not yet recruiting
- NCT06783816 — A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors · NA · recruiting
Other recruiting trials for Lymphoma, B-Cell
Currently open trials in the same condition.
- NCT06954805 — Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD) · Phase 2 · recruiting
- NCT06609304 — Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma · Phase 4 · recruiting
- NCT06866873 — CD-19 CAR-T Cell for Pediatric ALL or Lymphoma · NA · recruiting
- NCT06381830 — Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma · Phase 2 · recruiting
- NCT05797233 — Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies · Phase 1 · active not recruiting
Other Shanxi Bethune Hospital trials
Trials by the same sponsor.
- NCT07371533 — Clinical Study of Recombinant Anti-CD19m-CD3 Antibody Injection (A-319) · NA · not yet recruiting
- NCT07514052 — Predicting Response to Selinexor-Based Therapy in Relapsed/Refractory Multiple Myeloma: A Multicenter Prospective Study · recruiting
- NCT07239375 — Intraosseous Infusion in Hematologic Critical Patients · recruiting
- NCT07265037 — Integrated TCM - Western Medicine Strategy for Long - Distance Diabetes Management · NA · recruiting
- NCT07497165 — Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06850285 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanxi Bethune Hospital
- Last refreshed: 27 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06850285.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing